Moving beyond the Cox proportional hazards model in survival data analysis: a cervical cancer study

Lixian Li, Zijing Yang, Yawen Hou, Zheng Chen

ABSTRACT

Objectives This study explored the prognostic factors and developed a prediction model for Chinese-American (CA) cervical cancer (CC) patients. We compared two alternative models (the restricted mean survival time (RMST) model and the proportional baselines landmark supermodel (PBLS model, producing dynamic prediction)) versus the Cox proportional hazards model in the context of time-varying effects.

Setting and data sources A total of 713 CA women with CC and available covariates (age at diagnosis, International Federation of Gynecology and Obstetrics (FIGO) stage, lymph node metastasis and radiation) from the Surveillance, Epidemiology and End Results database were included.

Design We applied the Cox proportional hazards model to analyse the all-cause mortality with the proportional hazards assumption. Additionally, we applied two alternative models to analyse covariates with time-varying effects. The performances of the models were compared using the C-index for discrimination and the shrinkage slope for calibration.

Results Older patients had a worse survival rate than younger patients. Advanced FIGO stage patients showed a relatively poor survival rate and low life expectancy. Lymph node metastasis was an unfavourable prognostic factor in our models. Age at diagnosis, FIGO stage and lymph node metastasis represented time-varying effects from the PBLS model. Additionally, radiation showed no impact on survival in any model. Dynamic prediction presented a better performance for 5-year dynamic death rates than did the Cox proportional hazards model.

Conclusions With the time-varying effects, the RMST model was suggested to explore diagnosis factors, and the PBLS model was recommended to predict a patient’s 5-year dynamic death rate.

INTRODUCTION

According to Surveillance, Epidemiology and End Results (SEER) Cancer Statistics Review, 13,170 estimated new cases of cervical cancer (CC, 0.7% of all new cancer cases) and 4,250 estimated new deaths (0.7% of all new cancer deaths) will occur in 2019, making it the third most common cancer diagnosis and cause of death among gynaecological cancers in the USA. With the development of human papillomavirus (HPV) vaccine, the incidence of CC will likely continue to decline both in the USA and worldwide. Unfortunately, despite these advances, Asian Americans are often reported to have low CC screening rates and high cancer mortality rates. Among the Asian-American subgroups, the Chinese-American (CA) subgroup is the largest population and the fifth fastest-growing racial population in the USA. However, few studies are available in the literature regarding exploitation of the risk factors and prognosis of CC for CA women. Therefore, a survival model specifically for CA women with CC would be widely useful and clinically beneficial.

The Cox proportional hazards (PHs) model is the most common regression modelling framework to explore prognostic factors and to estimate survival rates. Importantly, the Cox PHs model has to satisfy the PHs assumption, which means that the ratio of the two hazard functions is constant over time. However, Trinquart et al found evidence of the non-proportionality of hazards (i.e., the HR is not constant over time) in 24% (13/54) of trials.
published in five leading oncology journals. In such situations, a constant HR (averaged HR over the follow-up) from the Cox PHs model may result in misleading conclusions.\textsuperscript{5,7}

In recent years, except for the HR from the Cox PHs model, several authors\textsuperscript{8-11} have advocated the restricted mean survival time (RMST) difference as a robust and clinically interpretable summary measure of the survival time distribution that does not rely on the PHs assumption. By definition, the RMST is the mean survival time to a prespecified time point ($\tau$) and can be evaluated as the area under the survival curve $S(t)$ up to this restricted survival time ($\tau$).\textsuperscript{9,10} When the event of interest is death, it can be explained easily as ‘$\tau$-year life expectation’. Thus, we also applied the RMST differences to explore prognostic factors in CA CC.

However, the above two models cannot be used to predict from an arbitrary prediction time point ($s$) during the follow-up period, as the models have been designed for using immediately after diagnosis.\textsuperscript{15} For example, patients may pay more attention to the survival probability or mortality of ‘$w$’ years after a cancer diagnosis, which is often asked by the question ‘How long will I live?’ or ‘What is the probability of being alive ‘$w$’ years from now?’ . Furthermore, the question is asked at the start of the treatment as well as at any time during the follow-up visits. This question, which implies a conditional probability of surviving an additional $w$ years, given that the patient is still alive at that time point,\textsuperscript{13-14} emphasises the ability of surviving an additional $w$ years, given that the patient is still alive at that time point.\textsuperscript{13-14} Houwelingen and Putter\textsuperscript{16,17} designed the proportional baselines landmark supermodel (PBLMS model; dynamic prediction) based on the Cox PHs model, considering time-varying effects. Thus, we can use this model to obtain individual death rates after an arbitrary time point $s$ during follow-up. This concept of continually updating the $w$-year death rate from a certain $s$ is referred to as the $w$-year dynamic death rate (DDR).

One aim of this article was to explore the effect of variation in prognostic factors over time on overall survival and to obtain the 5-year DDR for CA CC patients based on the SEER data. Another aim was to introduce two alternative methods when the PHs assumption failed and to provide statistical suggestions that could assess risks and predict survival probability for clinicians and patients.

**METHODS**

**Data sources**

The SEER programme of the National Cancer Institute is an authoritative source of information on cancer incidence and survival in the USA that includes patient demographics, tumour characteristics, treatment utilisation and mortality. It is currently collecting and publishing cancer data from population-based cancer registries covering approximately 30% of the US population from 2013. The SEER database is an open public database, and the release of data from the SEER database does not require informed patient consent as patient privacy information is protected by the SEER cancer registries in every state of the USA. Access to the SEER 9 database was obtained after execution of a signed SEER Research Data Use Agreement (DUA).

**Study design**

Women diagnosed with CC were identified using the International Classification of Diseases for Oncology third Edition (ICD-O-3)\textsuperscript{18} codes, including cancer of the endocervix (C53.0), exocervix (C53.1), overlapping lesion of cervix uteri (C53.8) and unspecified cervix uteri cases (C53.9) for Chinese patients (863 cases) from 1988 to 2013. Patients with multiple primaries (0 case), autopsy only and death certificate only (4 cases), no survival time record (20 cases), not the first tumour (40 cases), unknown age at diagnosis (0 cases), unspecified International Federation of Gynecology and Obstetrics (FIGO) stage (36 cases), unknown lymph node metastasis (LNM) (75 cases) or unspecified radiation therapy (3 cases) were excluded (total number: 150 cases; some patients may miss several variables). Ultimately, 713 patients were involved in this analysis (see online supplementary eFigure 1).

**Patient and public involvement**

Patients were not involved in setting the research questions or planning the study. Researchers do not know the identities of the study participants.

**Statistical analysis**

The outcome of this analysis was all-cause mortality. The continuous variable (age at diagnosis) was indicated with median (range), and categorical data (FIGO stage, LNM and radiation therapy) were described using counts. The age at diagnosis was divided into per 10 years to better represent the covariate effect. The FIGO stage was dichotomised into categorical variables for easy statistical interpretation.

The Kaplan-Meier curves were graphed to describe overall survival. The univariable and multivariable Cox PHs models were used to estimate HRs and 95% CIs of the age at diagnosis, FIGO stage, LNM and radiation factors. Using the Grambsch-Therneau test,\textsuperscript{19} we found that the age at diagnosis and FIGO stage violated the PHs assumption, in which cases the interpretation of a constant HR was difficult. Therefore, RMST was used as another appropriate outcome measure in our analysis. We chose a restricted survival time ($\tau = 20$) first and then computed the pseudo-value for each observation and finally fitted a generalised linear model (GLM) to assess the prognostic factors.\textsuperscript{20}

For dynamic prediction analysis,\textsuperscript{16} we first fixed the prediction window at $w=5$ years—that is, the ‘$w$’ in response to the patient’s question ‘How long will I live?’ at any prediction time point ($s$). Next, we selected a set of prediction landmark time points $\{\tau_1, \ldots, \tau_{10}\}$ from prediction time point $s$ at approximately every 2.4 months between 0 and 20 years after the diagnosis of CC. For each landmark

**Li L, et al. BMJ Open 2020;10:e033965. doi:10.1136/bmjopen-2019-033965**
time point $s$, we constructed a landmark dataset $R_s$ which consisted of individuals still alive at $s$ with administrative censoring at $s + w$ (see online supplementary eFigure 2). These landmark data sets $R_s$ were stacked to create a super prediction data set $R$. We then applied a PBLs model to the stacked super dataset $R_s$, which allows the baseline hazard to change smoothly with the landmark time point. This model can be fitted directly by applying a simple Cox model to the dataset $R_s$ in which the landmark time point is used as a covariate. Using this analysis, we can obtain the 5-year DDR at any prediction time point, $s$, between 0 and 20 years after diagnosis of CC. In addition, to test for time-varying covariate effects, interactions between covariates and $s$ (both linear and quadratic) were also included in the PBLs model, and the Akaike information criterion (AIC) was used to decide the final model for dynamic prediction.

The performances of the prediction models (the Cox PHs model and the PBLs model ($w=5$)) were evaluated in terms of both discrimination and calibration. The model’s capacity to correctly discriminate among patients was evaluated using Harrell’s C-index, while the calibration using the heuristic shrinkage factor was based on 10,000 bootstrap resamplings.

All analyses employed R 3.2.4 software, and the significance level was set to 0.05.

**RESULTS**

**Characteristics of the study population**

The characteristics of the 713 CC patients with 162 (22.7%) deaths, with a long-term (nearly 26 years, i.e., the maximum follow-up time in this data) survival rate of 69.4% (95% CI 64.5% to 74.7%), are summarised in Table 1. The median age at diagnosis was 42 (15–97) years. The median death time and median follow-up time were 4.08 (range: 0.08–24.08) and 16.67 (range: 0.08–25.92) years, respectively.

**Effects of prognostic factors on overall survival**

According to the Cox PHs model, all covariates showed significant differences ($P<0.001$) in the univariate analysis, while the multivariate analysis demonstrated that radiation did not have a significant effect ($P=0.156$) on CC patients ($HR=1.43; 95\% CI 0.87$ to 2.33) (for more details, see online supplementary eFigure 3 and table 1). However, the Grambsch-Therneau test showed that the age at diagnosis and FIGO stage were covariates with time-varying effects, indicating that constant $HR$s for these covariates obtained from the Cox PHs model were unreliable.

Table 1 also shows the RMST differences. The patients without LNM had a longer restricted mean survival time, namely, 3.63 years, than the women presenting with LNM after 20 years of follow-up in the multivariate analysis. The women with FIGO stage II compared with patients with stage I showed a statistically significant RMST difference ($-3.04; 95\% CI -5.34$ to $-0.73$), while the $HR$ (1.57; 95\% CI 0.97 to 2.54) showed no significance in the multivariate analysis.

Table 2 demonstrates the regression coefficients in the PBLs model, and figure 1 shows the $HR^s(s)$s, that is, the $HR$ from any prediction time point $s$ to $s + 5$. The age at diagnosis revealed a changing impact on $HR^s(s)$ with each successive prediction time point ($s$), indicating that CC women had increased 5-year death rates over time (figure 1A). The women in FIGO stage I compared with stage II in situ illustrated a significant time-varying effect, while the stage II versus stage I and stage III versus stage I did not (figure 1B1–B3); however, the overall time-varying effect was significant. The LNM also had the potential to change over time in the 5-year dynamic $HR$, which could be calculated by the following formula:

$$HR^s_{\text{LNM}}(s) = \exp(\beta_0 + \beta_1 \times (s/20) + \beta_2 \times (s/20)^2)$$

The $HR^s_{\text{LNM}}(s)$ (figure 1C) increased from the start of the diagnosis but decreased 6 years after the diagnosis and was nearly 0 with a 20-year history of CC ($HR^s_{\text{LNM}}(5) = 3.38$ , $HR^s_{\text{LNM}}(10) = 2.32$, $HR^s_{\text{LNM}}(15) = 0.48$, $HR^s_{\text{LNM}}(20) = 0.03$). Radiation was not statistically significant (figure 1D).

**Individual dynamic prediction**

The 5-year DDRs for patients with different baseline characteristics (see online supplementary eTable 1) are shown in figure 2. For example, the green line in figure 2 represents the probability of dying within 5 years for patient B with the following characteristics: diagnosed at the age of 45 years, FIGO stage I, without LNM and no radiation. If still alive at 7 years after diagnosis, that is, the landmark time equaled 7 years, the probability of dying within 5 years was less than 0.05 for patient B.

**Model assessment**

The Cox PHs model and the PBLs model ($w=5$) presented different discrimination capacities (0.836 and 0.868, respectively, for the C-index). The PBLs model demonstrated a better discriminative capacity than the Cox PHs model. The calibration slopes (0.958 and 0.996, respectively) for these two models were similar for the apparent performance, while the PBLs model showed a better fit.

**DISCUSSION**

We used the Cox PHs model, as well as two alternative methods (the RMST difference model and the PBLs model), to explore the prognostic factors and provide 5-year DDR predictions for CA CC patients. To our knowledge, these two alternative models for CA CC patients have not been previously reported.

Regarding factor exploration, the Cox PHs model revealed that age at diagnosis, FIGO stage and LNM were independent risk factors of the prognosis of CA CC patients. However, the presence of non-PHs indicated that the effects of some covariates were changeable over time. In such a situation, RMST, the area under the survival
| Variable                                      | Baseline characteristics | Cox proportional hazards model | RMST based on pseudo-values (GLM) |
|----------------------------------------------|--------------------------|--------------------------------|-----------------------------------|
|                                              | No. of patients (deaths) | Univariable HR (95% CI) *     | Multivariable HR (95% CI) *       | Univariable RMST (95% CI)‡       | Multivariable RMST (95% CI)*    | P value†                        |
|                                              |                          |                               | P value†                          | P value†                         |                               |
| Age at diagnosis (per 10 years)              | 713 (162)                | 1.90 (1.72 to 2.10)§           | 1.59 (1.42 to 1.79)¶             | <0.001                           | −1.79 (−2.11 to −1.47)         | −1.06 (−1.43 to −0.69)         | <0.001 |
| FIGO stage                                   |                          |                                |                                  |                                  |                                |                                  |
| In situ                                      | 375 (44)                 | 0.29 (0.19 to 0.44)§           | 0.56 (0.35 to 0.88)¶             | 0.013                           | 3.01 (2.01 to 4.02)            | 1.35 (0.30 to 2.41)            | 0.012 |
| I (reference)                                | 205 (46)                 |                                |                                  |                                  |                                |                                  |
| II                                           | 101 (50)                 | 3.28 (2.19 to 4.92)§           | 1.57 (0.97 to 2.54)              | 0.067                           | −5.07 (−6.98 to −3.17)         | −3.04 (−5.34 to −0.73)         | 0.010 |
| III                                          | 32 (22)                  | 7.23 (4.32 to 12.12)           | 2.26 (1.23 to 4.15)¶             | 0.009                           | −9.64 (−12.70 to −6.58)        | −6.21 (−9.50 to −2.92)         | <0.001 |
| Lymph node metastasis                        |                          |                                |                                  |                                  |                                |                                  |
| No (reference)                               | 659 (132)                |                                |                                  |                                  |                                |                                  |
| Yes                                          | 54 (30)                  | 6.07 (4.04 to 9.12)            | 2.52 (1.61 to 3.94)              | <0.001                          | −7.93 (−10.31 to −5.55)        | −3.63 (−6.29 to −0.97)         | 0.008 |
| Radiation                                    |                          |                                |                                  |                                  |                                |                                  |
| No (reference)                               | 532 (77)                 |                                |                                  |                                  |                                |                                  |
| Yes                                          | 181 (85)                 | 7.36 (5.32 to 10.19)           | 1.43 (0.87 to 2.33)              | 0.156                           | −6.93 (−8.25 to −5.61)         | −1.09 (−3.05 to 0.86)          | 0.273 |

*Adjusted for the age at diagnosis, FIGO stage, lymph node metastasis and radiation.
†P values were obtained from the Wald test and adjusted for the age at diagnosis, FIGO stage, lymph node metastasis and radiation.
‡The intercepts for each variable are 24.96, 16.23, 17.26 and 18.42, respectively.
§Grambsch-Therneau proportional hazards test, P<0.05 for univariate analysis.
¶Grambsch-Therneau proportional hazards test, P<0.05 adjusted for age at diagnosis, FIGO stage, lymph node metastasis and radiation.
FIGO, International Federation of Gynecology and Obstetrics; GLM, generalised linear model; RMST, restricted mean survival time.
curve $S(t)$ up to the restricted time point ($\tau$), has great potential as another meaningful and sensitive outcome measure in the analysis with a time-to-event outcome. Compared with HR, the RMST difference does not rely on the PHs assumption and is readily interpretable. For instance, women without LNM had a longer mean survival time than the patients with LNM after the 20-year follow-up (blue area in online supplementary eFigure 4), namely, 7.93 years in the univariate analysis. In addition, the RMST is estimable even under heavy censoring, while the CI for HR from the Cox PHs model can be unstable and can vary widely. However, satisfactory results of RMST analysis must depend on the choice of the restricted time point ($\tau$). Generally, the value of $\tau$ should be prespecified to avoid selection bias (after seeing the data). An appropriate time point should consider both the statistical method and the clinical reality. For example, in a trial on a severe cancer, 1-year or 2-year survival may be an appropriate measure, so $\tau=1$ year or 2 years would be reasonable, while for cancers with a relatively longer clinical course, such as CC, $\tau=10$ or even 20 years is more realistic. In the absence of such a choice, a default $\tau$ may be taken to be slightly below the maximum expected follow-up time. In summary, the HR and RMST difference are complementary techniques that provide alternative methods of summarising treatment effects.

There are also some other models that are commonly used when the PHs assumption fails, such as the accelerated failure time (AFT) model and the transformation model. However, these two models have certain limitations in their use and their results are not easy to interpret. For example, although the AFT model is simple and does not need to meet the PHs assumption, the distribution of survival time must be specified in advance, and random errors, noise and covariates are assumed to be independent and so on. Due to the special distribution of the survival time in the data in this study (for more details, see online supplementary eFile 1), the results may not be accurate. The transformation model also has some advantages and has proved its relevance in the two special cases (the Cox PHs model and the proportional odds model; for details, see online supplementary eFile 1), but for other choices of $r$, the regression coefficients are more difficult to interpret because they refer to the scale given

### Table 2 The dynamic prediction used the PBLS model ($w=5$ years)

| Variable                  | Time function* | Coefficient | SE  | $P$ value† | $P$ value‡ |
|---------------------------|----------------|-------------|-----|------------|------------|
| $\beta_{LM}$ ($s$)        |                | 1           | 0.18| 0.11       | 0.082      |
| Age at diagnosis (per 10 years) |                | s/20        | 1.14| 0.25       | <0.001     |
| FIGO stage (1994 edition) |                |             |     |            | <0.001     |
| In situ                   |                | 1           | -2.39| 0.55       | <0.001     |
| s/20                      |                |             |     |            | <0.001     |
| $(s/20)^2$                |                |             |     |            | <0.001     |
| I (reference)             |                | 1           | 0.39| 0.40       | 0.335      |
| s/20                      |                |             |     | 2.68       | 2.79       |
| $(s/20)^2$                |                |             |     | -3.44      | 3.14       |
| III                       |                | 1           | 1.08| 0.44       | 0.015      |
| s/20                      |                |             |     | 2.20       | 4.69       |
| $(s/20)^2$                |                |             |     | -18.40     | 11.22      |
| Lymph node metastasis     |                |             |     |            | <0.001     |
| No (reference)            |                | 1           | 0.40| 0.40       | 0.316      |
| Yes                       |                | s/20        | 5.66| 3.15       | 0.072      |
| $(s/20)^2$                |                |             |     | -9.56      | 4.00       |
| Radiation                 |                |             |     |            | 0.17       |
| No (reference)            |                | 1           | 0.34| 0.30       | 0.260      |
| Yes                       |                | s/20        | -10.60| 1.89     | <0.001     |
| $(s/20)^2$                |                |             |     | 3.50       | 1.55       |

* Time function: $\beta_{LM}(s) = \beta_0 + \beta_1(s/20) + \beta_2(s/20)^2$.
† $P$ value for the time-varying trend.
‡ $P$ value for the whole time-varying effect adjusted for age at diagnosis, FIGO stage, lymph node metastasis and radiation.

FIGO, International Federation of Gynecology and Obstetrics; PBLS, proportional baselines landmark super.
Exploring the prognostic factors is important for clinical research, but a good prognostic prediction model might be more important to patients. We used the PBLS model to perform dynamic prediction and it had several strengths over the above two models. First, the PBLS model can effectively find the time-varying effect of covariates for both estimation and prediction (see table 2 and figure 1). Second, patients may focus more on ‘What is the probability of still being alive w years from now?’ during the follow-up. The PBLS model can provide the $HR^w(s)$ or $w$-year DDR at different prediction times. The Cox PHs model in this analysis could only provide a static $HR$ for the whole follow-up and obtain the 5-year survival rate from the diagnosis time to 5 years. Furthermore, the discrimination and calibration in the PBLS model were clearly larger than those in the Cox PHs model, indicating that PBLS is more suitable in reality than the Cox PHs model for prediction when the PHs assumption is unsatisfied. Third, dynamic prediction is based on landmark analysis; thus, this model could overcome the guarantee time bias, especially in the group classification.

However, dynamic prediction must be considered cautiously. We noticed that the dramatic 5-year dynamic $HR$ for the dummy variable (FIGO III vs FIGO I) was less than 1 after 7.4 years. The reason is that, at each landmark time point ($s$), we have a corresponding dataset ($R_s$) (see online supplementary eFigure 6). As the landmark time point increased, the patients whose survival times were less than $s$ would be excluded, leading to a decrease in the number of patients in the dataset $R_s$. The cumulative distribution function ($F(s)$) (see online supplementary eFigure 7) was calculated by dividing the number of deaths by the number of patients in each dataset. It can be seen that, for FIGO III, $F(s)$ became 0 after a 7.4-year follow-up as the number of deaths equals 0. Thus, the reason for the dramatic $HR^5(s)$ less than 1 after 7.4 years was apparent. Therefore, we could not simply state that the patients in FIGO III had better survival than those in FIGO I at the late follow-up.

In addition, several limitations of the current study must be noted. First, this is a retrospective observational study, and consequently, some bias may have affected the analysis. Second, SEER database lacks some important variables related to patient status, such as HPV infection, the information of chemotherapy, and economic conditions, which are associated with prognosis. Third, because SEER does not include information on cancer recurrence, we are unable to analyse other endpoints, such as time to recurrence, or disease-free survival. However, because cause-of-death information is available, an additional cause-specific analysis was performed to model CC mortality (for details, see online supplementary eFile 7).

Figure 1 Dynamic $HR$s with 95% CIs in the dynamic prediction PBLS model ($w=5$ years). The red line represents $HR=1$. The black solid line represents dynamic $HR$s, and the black dashed line represents 95% CIs. FIGO, International Federation of Gynecology and Obstetrics; PBLS, proportional baselines landmark super.

Figure 2 Changes in the 5-year dynamic death rate in nine example patients. FIGO, International Federation of Gynecology and Obstetrics.
2), and the results are shown in online supplementary eTables 4–7, eFigures 8 and 9.

Above all, older patients had a worse survival rate than younger ones, a finding similar to that of Nghiem VT for Chinese patients. The FIGO stage is an essential prognostic factor in CC patients, and our study confirmed that advanced FIGO stage patients had a poor survival rate.22 23 LNM was an unfavourable prognostic factor in our models. Several studies24 25 have indicated that patients with LNM have a rather poor prognosis. The new finding that age at diagnosis, FIGO stage and LNM have time-varying effects was found from the dynamic prediction. In this study, radiation had no impact on survival in CA CC, a finding that differs by race in some reports.26 27

In summary, the Cox PHs model is unsuitable for survival analysis when the PHs assumption is unsatisfied; thus, the RMST difference as another effective outcome measure that overcomes the PHs handicap, which would help clinicians to explore the effects of prognostic factors for CA CC, and the PBLS model (dynamic prediction) permits continuous revision of a CA CC patient’s 5-year DDR at the start of the diagnosis as well as at different prediction times s during follow-up. We also recommend the latter two alternatives considering time-varying factors when the PHs assumption is not satisfied. But in actual use process, we must pay attention to the choice of the restricted time point (τ) in the RMST model and the interpretation of the PBLS model.

Acknowledgements The authors would like to thank two referees and the associate editor for their constructive advice.

Contributors Conception and design: ZC, LL and ZY; acquisition of data: ZC; analysis and interpretation of data: LL, ZY and ZC; writing, review, and revision of the manuscript: LL, ZY, YH and ZC; all authors have read and approved the manuscript.

Funding This work was supported by the National Natural Science Foundation of China (grant number 81672306, 81903411), Natural Science Foundation of Guangdong Province (grant number 2018A030313849) and the Guangdong Basic and Applied Basic Research Foundation (grant number 2019A1515011506).

Competing interests None declared.

Patient and public involvement Patients and/or the public were not involved in the design, or conduct, or reporting, or dissemination plans of this research.

Patient consent for publication Not required.

Ethics approval The data analyses and use of the SEER 9 database in our manuscript are in accordance with the DUA and do not require institutional review board approval or other ethics approval or consent of the study subjects.

Provenance and peer review Not commissioned; externally peer reviewed.

Data availability statement Data may be obtained from a third party and are not publicly available. This study used data obtained from the Surveillance, Epidemiology, and End Results program of the U.S. Department of Health and Human Services, National Institutes of Health, National Cancer Institute.

Open access This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/.

ORCID iD Zheng Chen http://orcid.org/0000-0003-3201-2666

REFERENCES

1 SEER Cancer Statistics Factsheets: Cervix Cancer. National cancer Institute. Bethesda, MD.
2 Robison K, Clark L, Eng W, et al. Cervical cancer prevention: Asian-American women’s knowledge and participation in screening practices. Women’s Health Issues 2014;24:e231–4.
3 Fang CY, Ma GX, Tan Y. Overcoming barriers to cervical cancer screening among Asian American women. N Am J Med Sci 2011;4:77–83.
4 Nghiem VT, Davies KR, Chan W, et al. Disparities in cervical cancer survival among Asian-American women. Ann Epidemiol 2016;26:28–35.
5 Trinquart L, Jacot J, Conner SC, et al. Comparison of treatment effects measured by the hazard ratio and by the ratio of restricted mean survival times in oncology randomized controlled trials. J Clin Oncol 2016;34:1813–9.
6 Hasegawa T, Uno H, Wei L-J. Nivolumab in Non-squamous non-small-cell lung cancer. N Eng J Med 2016;374:492–3.
7 Hernán MA. The hazards of hazard ratios. Epidemiology 2010;21:13–15.
8 A’Hern RP. Restricted mean survival time: an obligatory end point for time-to-event analysis in cancer trials? J Clin Oncol 2016;34:3474–6.
9 Royston P, Parmar MKB. The use of restricted mean survival time to estimate the treatment effect in randomized clinical trials when the proportional hazards assumption is in doubt. Stat Med 2011;30:2409–21.
10 Royston P, Parmar MKB. Restricted mean survival time: an alternative to the hazard ratio for the design and analysis of randomized trials with a time-to-event outcome. BMC Med Res Methodol 2013;13:152.
11 Zhao L, Claggett B, Tian L, et al. On the restricted mean survival time curve in survival analysis. Biometrics 2016;72:215–21.
12 Fontein DBY, Klinten Grand M, Nortier JWR, et al. Dynamic prediction in breast cancer: proving feasibility in clinical practice using the team trial. Ann Oncol 2015;26:1254–62.
13 Zamboni BA, Yothers G, Choi M, et al. Conditional survival and the choice of conditioning set for patients with colon cancer: an analysis of NSABP trials C-03 through C-07. J Clin Oncol 2010;28:2544–8.
14 Hieke S, Kleber M, König C, et al. Conditional survival: a useful concept to provide information on how prognosis evolves over time. Clin Cancer Res 2015;21:1550–6.
15 Yang Z, Hou Y, Lyu J, et al. Dynamic prediction and prognostic analysis of patients with cervical cancer: a landmarking analysis approach. Ann Epidemiol 2020;44:45–51.
16 van Houwelingen HC, Putter H. Dynamic prediction in clinical survival analysis. CRC Press, 2012.
17 Van Houwelingen HC. Dynamic prediction by Landmarking in event history analysis. Scand J Stat 2007;34:70–85.
18 Fritz A, Percy C, Jack A, et al. International classification of diseases for oncology (ICD-O) (ED 3). Geneva: World Health Organization, 2000.
19 Grambsch PM, Therneau TM. Proportional hazards tests and diagnostics based on weighted residuals. Biometrika 1994;81:515–26.
20 Klein JP, Gerster M, Andersen PK, et al. Sas and R functions to compute pseudo-values for censored data regression. Comput Methods Programs Biomed 2006;89:289–300.
21 Giobbie-Hurder A, Gelber RD, Regan MM. Challenges of guarantee-time bias. J Clin Oncol 2013;31:2963–9.
22 Galic V, Herzog TJ, Levin SN, et al. Prognostic significance of adenocarcinoma histology in women with cervical cancer. Gynecol Oncol 2012;125:287–91.
23 Hsu HC, Li X, Curtin JP, et al. Surveillance epidemiology and end results analysis demonstrates improvement in overall survival for cervical cancer patients treated in the era of concurrent chemoradiotherapy. Front Oncol 2015;5:81.
24 Tattersall MH, Ramirez C, Coppleson M. A randomized trial of adjuvant chemotherapy after radical hysterectomy in stage IB-IIA cervical cancer patients with pelvic lymph node metastases. Gynecol Oncol 1992;46:176–81.
25 Kim SM, Choi HS, Byun JS. Overall 5-year survival rate and prognostic factors in patients with stage Ib and IIa cervical cancer treated by radical hysterectomy and pelvic lymph node dissection. Int J Gynecol Cancer 2000;10:305–12.
26 Lindegaard JC, Thranov IR, Engelholm SA. Radiotherapy in the management of cervical cancer in elderly patients. Radiother Oncol 2000;56:9–15.
27 Ikushima H, Takegawa Y, Osaki K, et al. Radiation therapy for cervical cancer in the elderly. Gynecol Oncol 2007;107:339–43.